Co-expressing Class XIV Myosin with Co-chaperones for Parasite Motility Studies
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective means to prepare and utilize functional class XIV myosins, which are crucial for understanding and inhibiting the motility of apicomplexan parasites like Toxoplasma gondii, as the mechanism of their motor complex and the role of associated proteins remain unclear.
Innovation Solution
The method involves co-expressing polynucleotides encoding for class XIV myosin heavy chain, light chains, and co-chaperone proteins in an expression system to produce functional class XIV myosin polypeptides, allowing for the assembly and characterization of the myosin motor complex, including the use of specific tags for detection and purification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Device complexity
If class XIV myosin is expressed in traditional expression systems, then the complexity of the expression system is reduced, but the functional activity of the myosin complex is lost
Solution Approach 1:
The patent merges multiple polynucleotides encoding class XIV myosin heavy chain, light chains, and co-chaperone proteins into a co-expression system. This combining of multiple genetic elements allows the reconstitution of the functional myosin complex in a heterologous expression system, resolving the contradiction between system simplicity and functional integrity by integrating necessary components into a unified expression framework
Solution Approach 2:
The patent introduces co-chaperone proteins as intermediary components that facilitate the proper folding and assembly of the myosin complex. These co-chaperones act as mediators between the expressed myosin subunits, enabling functional complex formation in the heterologous expression system without requiring the native parasite cellular environment
2Reliability
If the mechanism of the myosin motor complex is studied in native parasites, then the functional context is preserved, but the ability to manipulate and characterize individual components is limited
Solution Approach 1:
The patent segments the myosin motor complex into individual polynucleotide components encoding heavy chain, light chains, and co-chaperones. This segmentation allows independent manipulation, expression, and characterization of each component while maintaining the ability to reassemble them into functional complexes, thus enabling detailed mechanistic studies that are not feasible in native parasites
Solution Approach 2:
The patent creates a universal expression system that can produce functional myosin complexes heterologously. This multi-functional approach allows the same expression framework to be used for producing, purifying, and characterizing myosin components under controlled conditions while preserving their native functional properties, bridging the gap between in vivo context and in vitro manipulability
3Ease of manufacture
If class XIV myosin is expressed without co-chaperone proteins, then the expression process is simplified, but the assembly of functional myosin complex is impaired
Solution Approach 1:
The patent incorporates co-chaperone protein expression into the co-expression framework before myosin complex assembly occurs. By preliminarily providing the necessary chaperone components, the system ensures proper folding and assembly of the myosin complex is facilitated from the outset, preventing aggregation or misfolding that would occur in simplified expression systems lacking these essential auxiliary proteins
Data Source
AI summary
The invention, in part, includes methods and compounds useful to prepare and functional class XIV myosin. Functional class XIV myosin prepared using methods of the invention may be useful to screen for and identify compounds that inhibit and treat parasitic infections and contamination.